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Abstract 
Background: NK cells can destroy tumor cells without prior sensitization or immunization. Tumors often lose expres-
sion of MHC molecules and/or antigens. However, NK cells can lyse tumor cells in a non-MHC-restricted manner and 
independent of the expression of tumor-associated antigens. NK cells are therefore considered ideal for adoptive 
cancer immunotherapy; however the difficulty of obtaining large numbers of fully functional NK cells that are safe 
to administer deters its clinical use. This phase I clinical trial seeks to address this obstacle by first developing a novel 
system that expands large numbers of highly activated clinical grade NK cells, and second, determining if these cells 
are safe in a mono-treatment so they can be combined with other reagents in the next round of clinical trials.
Methods: Patients with unresectable, locally advanced and/or metastatic digestive cancer who did not succeed with 
standard therapy were enrolled. NK cells were expanded ex vivo by stimulating PBMCs with OK432, IL-2, and modified 
FN-CH296 induced T cells. Patients were administered autologous natural killer cell three times weekly via intravenous 
infusions in a dose-escalating manner (dose 0.5 × 109, 1.0 × 109, 2.0 × 109 cells/injection, three patients/one cohort).
Results: Total cell population had a median expansion of 586-fold (range 95–1102), with a significantly pure (90.96 %) 
NK cell population. Consequently, NK cells were expanded to approximately 4720-fold (range 1372–14,116) with cells 
being highly lytic in vitro and strongly expressing functional markers such as NKG2D and CD16. This NK cell therapy 
was very well tolerated with no severe adverse events. Although no clinical responses were observed, cytotoxicity of 
peripheral blood was elevated approximately twofolds up to 4 weeks post the last transfer.
Conclusion: We successfully generated large numbers of activated NK cells from small quantities of blood without 
prior purification of the cells. We also determined that the expanded cells were safe to administer in a monotherapy 
and are suitable for the next round of clinical trials where their efficacy will be tested combined with other reagents.
Trial Registration: UMIN UMIN000007527
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Background
Natural killer (NK) cells play critical roles in the early 
innate response to pathogens and tumor cells [1, 2]. 
These cells exhibit strong cytotoxic activity against tumor 
cells without prior sensitization or immunization, and 
produce numerous cytokines resulting in the subsequent 
activation of the adoptive immune system.
Tumors often lose expression of tumor-associated anti-
gens and/or MHC molecules as a means of immune escap-
ing detection by T cells [3–5]. NK cells can lyse tumor cells 
in a non-MHC-restricted manner and are independent of 
the expression of tumor-associated antigens. Due to this, 
NK cells are considered ideal for adoptive cancer immu-
notherapy. In contrast to vaccine therapy or antigen-spe-
cific adoptive T cell therapy, it is not necessary to identify 
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target tumor antigen for NK cell-based immunotherapy; 
this makes it more universally applicable and particularly 
effective for treating solid tumors that frequently lose 
tumor-associated antigens and/or self-MHC molecules. 
NK cell-based immunotherapy has been recommended as 
a means to improving hematologic malignancies [6, 7] and 
solid tumors [8–12] in clinical settings.
NK cells seem to possess many advantages that would 
make it ideal for clinical application. However, existing 
drawbacks are that it is difficult to generate large num-
bers of fully functional NK cells, and a standard method 
of ex  vivo NK cell expansion has not been established 
yet. T cells can be expanded more than 1000-fold ex vivo 
using anti-CD3 monoclonal antibody in combination 
with cytokines and other stimuli [13, 14]. However in 
general, NK cells cannot sustain proliferation, therefore, 
their proliferative responses to cytokines with or with-
out being co-cultured with other cells is modest and 
temporary [15–17]. To overcome this obstacle, research-
ers are seeking to develop new methods to obtain larger 
populations of highly pure NK cells. Examples include 
the ex vivo expansion of NK cells from (1) leukapheresis 
products by immunomagnetic beads selection [18–20], 
(2) from hematopoietic stem and progenitor cells from 
umbilical cord blood [21, 22], and (3) cytokine-based 
expansion method co-cultured with transgenic or irradi-
ated tumor cells, and irradiated peripheral blood mono-
nuclear cells [23, 24]. While these methods [18–24] have 
some merit, they have major drawbacks including: low 
expansion scale [20], low purity of NK cells [24], high 
cost [18–20], complicated procedures [18–24], and safety 
issues for human administration [23]. Developing inno-
vative strategies to generate clinically relevant pure NK 
cells in large numbers would provide an important break-
through in NK cell-based immunotherapy.
With this in mind, we recently developed a novel clin-
ical-grade NK cell expansion system using recombinant 
human fibronectin fragment (FN-CH296, RetroNectin®)-
induced T-cells (RN-T cells) as a stimulator. This method 
delivered a 688  ±  76-fold expansion of total cells in 
a sample of 31 cancer patients with purity levels of 
84.7 ± 3.6 % without prior purification (Additional file 1: 
Table S1) [25]. Moreover, the majority of expanded cells 
highly expressed functional markers such as NKG2D 
(97.3  ±  0.6  %) and CD16 (96.8  ±  0.7  %) and exerted 
strong cytotoxicity in  vitro and in experimental models 
of human tumors [25]. Having successfully produced 
these high quality NK cells, our secondary goal was to 
evaluate their safety when administered to patients with 
advanced digestive cancers and also assessed their effi-
cacy as a minor objective.
The maximum tolerated dose for NK cells has not 
yet been established and no general range has been 
suggested. In fact, there is conflicting data surround-
ing the maximum tolerated dose. In prior research the 
administration of a large number of NK cells (almost 
5–25 ×  109 cells for 50  kg patient) in conjunction with 
lymph depleting chemotherapy and systemic IL-2 admin-
istration was found to be effective and safe [6–8]. On the 
other hand, severe adverse events have been reported 
when fewer (0.4–2.0  ×  109 cells for 50  kg patient) NK 
cells were administered [8]. Taking these conflicting 
results into consideration, in this phase I clinical study, 
we evaluated the safety of autologous NK cells generated 
by our novel system by administered advanced digestive 
cancer patients with 0.5–2.0 ×  109 cells (a similar dose 




Patients with un-resectable, locally advanced and/or met-
astatic digestive cancer that was histologically confirmed 
were enrolled in this study. All patients had failed prior 
standard therapy and were recruited between Septem-
ber 2012 and June 2013. Eligibility criteria included: age 
>20 years, Eastern Cooperative Oncology Group (ECOG) 
performance status ≤2, no plans to receive chemotherapy 
other than oral fluorouracil prodrugs or radiation therapy, 
a life expectancy of at least 3  months, absence of seri-
ous cardiovascular disease, adequate vital organ function 
as indicated by leukocyte count ≥3000/mm3, neutro-
phil count ≥1500/mm3, platelet count ≥100,000/mm3, 
hemoglobin ≥9.0 g/dL, serum aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) ≤100  IU/L, 
serum total bilirubin ≤2  mg/dL, serum creatinine 
≤1.5  mg/dL, and blood urea nitrogen level ≤25  mg/dL. 
Patients were excluded if they tested positive for hepatitis 
B or C virus, HIV, HTLV-1, syphilis infection, had active 
severe infection, serious complications such as severe 
diabetes mellitus, unstable angina or myocardial infarc-
tion within 3  months, were pregnant or lactating, had a 
medical history of severe hypersensitivity or autoimmune 
disease.
Study design
This was a non-randomized, open label, phase I clinical 
trial with dose escalation of NK cells. The primary end-
point of this study was to assess the safety of the NK cells 
derived from our method, and the secondary end-points 
were clinical and immunological responses. This study 
was approved by the ethics committee of Kyoto Pre-
fectural University of Medicine. The trial was designed 
and conducted in accordance with the Helsinki Decla-
ration and the Ethical Guidelines for Clinical Research 
(the Ministry of Health, Labor and Welfare, Japan). All 
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participants provided written informed consent. This 
trial was registered as the University Hospital Medical 
Information Network (UMIN) Clinical Trial Registry as 
ID: UMIN000007527.
Cell processing
Preparation of the FN-CH296 (RetroNectin®)-stimulated 
T (RN-T) cells.
Peripheral blood (10–20 mL) was taken from each can-
cer patient. FN-CH296 (RetroNectin®, Takara Bio, Shiga, 
Japan)-stimulated T (RN-T) cells were prepared by a pre-
viously described method [13]. Briefly, peripheral blood 
mononuclear cells (PBMCs) were separated using Ficoll-
Paque PREMIUM (GE Healthcare, Tokyo, Japan). Subse-
quently, 2 × 106 of cells were re-suspended in GT-T551 
culture medium (Takara Bio) containing heat-inactivated 
autologous plasma (0.5  %) and recombinant IL-2 (Pro-
leukin; NovartisPharma, Nürnberg, Germany), then 
transferred to a cell-culture immobilized with both anti-
CD3 mAb (OKT3: Janssen Pharmaceutical k.k, Tokyo, 
Japan) and FN-CH296. On day 4, the cells were trans-
ferred to CultiLife® 215 bag (Takara Bio), and diluted 
with GT-T551 medium containing plasma (0.5  %) and 
IL-2 every 3 or 4 days. Cells were cultured for 1–2 weeks, 
γ-irradiated and then used as stimulators for NK-cell 
expansion.
Large‑scale expansion of NK cells
PBMCs were obtained from the peripheral blood (20–
40 mL) of each cancer patient. Subsequently, 5.6 × 106 of 
PBMCs were re-suspended in GT-T507α culture medium 
supplemented with heat-inactivated autologous plasma 
(1.0 %), IL-2 and OK-432 (Picibanil: Chugai Pharmaceu-
tical Co, Tokyo, Japan). Cells were then transferred to a 
cell-culture flask and RN-T cells as a stimulator were 
added. On day 7, the cultured cells were transferred to 
a CultiLife® 215 bag and stimulated again by RN-T cells 
in GT-T510 culture medium (Takara Bio) supplemented 
with heat-inactivated autologous plasma (1.0 %) and IL-2. 
On day 11, the cells were transferred to a CultiLife® Eva 
bag (Takara Bio), and GT-T510 containing plasma (1.0 %) 
and IL-2 were added. Cells were then expanded by add-
ing GT-T510 medium and increasing the number of 
CultiLife® Eva bag as necessary. On days 21 and 22, the 
cultured cells were harvested, washed and re-suspended 
in 100 mL of a saline based-solution supplemented with 
1 % of human serum albumin (Albuminar; CSL Behring, 
PA, USA) then administered to patients immediately.
Quality control testing was conducted by assessing 
samples taken during the culture period and the final 
product for sterility by the BacT/ALERT (bioMérieux, 
Durham, NC, USA) microbiological detection system 
and for mycoplasma contamination by a MycoAlert 
Mycoplasma Detection Kit (Lonza Japan, Tokyo, Japan). 
Sterility tests were contracted to FALCO Biosystems 
(Kyoto, Japan). The viability of expanded cells was meas-
ured by trypan blue exclusion assay, and tested for endo-
toxin by a kinetic colorimetric LAL assay. After thawing, 
a small aliquot of the final product was used for in vitro 
cytotoxicity assay; it was cryo-preserved and examined 
to identify the proportions of CD3−CD56+ cells and 
other cell surface markers by flow cytometry.
Treatment protocol
The eligibility criteria for transferred cells was as fol-
lows: ① The cultured cell viability was more than 80  %. ② The mean purity value of the three cultured cells was 
more than 50 %. ③ The number of transferred cells was 
70–130 % of the number that was set in each cohort. The 
patients were divided into three cohorts of three to four 
patients each: Cohort 1, 0.5 × 109 cells per dose; Cohort 
2, 1.0 × 109 cells per dose; and Cohort 3, 2.0 × 109 cells 
per dose. Expanded NK cells that passed quality tests 
were intravenously injected for 60  min on days 0, 7, 14 
(Fig. 1). We investigated the dose-limiting toxicity (DLT) 
occurring over a 28-day period after the third cell infu-
sion. DLT was defined as grade ≥3 for any adverse event 
related to the administration of cultured cells. If no DLT 
was observed in the previous cohort, another cohort 
was treated at the next higher dose. There was no intra-
patient dose escalation in this study.
Phenotypic analysis
The phenotype of expanded cells and PBMCs at base-
line (day 0), before the 3rd administration (day 14), and 
4  weeks after 3rd administration (day 42) were ana-
lyzed by flow cytometry. Monoclonal antibodies specific 
for CD3, CD16, CD56 (Beckman Coulter, CA, USA), 
NKG2D (eBioscience, CA, USA), CXCR3 (R&D sys-
tem, MN, USA), CXCR4 (Becton–Dickinson, CA, USA), 
CX3CR1 (Bio Legend, CA, USA) were applied. Each 
monoclonal antibody was conjugated as follows: CD3 
CD16, CD69, CXCR3 with fluorescein isothiocyanate 
(FITC)-, CD56, NKG2D, CXCR4, CX3CR1 with phyco-
erythrin (PE)-, CD3 with phycoerythrin-Cyanin 5 (PE-
Cy5)-, CD56 with phycoerythrin-Cyanin 7 (PC7-Cy7)-. 
Cells were analyzed by Cytomics FC500 (Beckman Coul-
ter) and data were acquired by the CXP software, version 
2.2 (Beckman Coulter) according to the manufacturer’s 
instruction.
Whole blood cytokine assay
Blood samples were obtained from patients on day 0 
and on day 42 after the 3rd administration. All plasma 
samples were stored at −80 °C until they were analyzed. 
Following the manufacturer’s instructions, we used a 
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Bio-Plex multiplex cytokine array system (Bio-Rad Labo-
ratories, CA, USA) with a panel that quantified the fol-
lowing 27 cytokines: IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, 
basic FGF, eotaxin, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-
1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF. 
Data acquisition and analysis were performed with Bio-
Plex Manager Software (version 5.0).
In vitro cytotoxicity assay
Blood samplings for in vitro cytotoxicity assay were done 
on day 0, before the 3rd administration (day 14) and on 
42 days after the 3rd administration (4 weeks). To evalu-
ate the cytotoxicity of expanded NK cells (final prod-
ucts) fresh PBMCs against K-562 cell as target cell was 
assayed using DELFIA® cell cytotoxicity kit (PerkinElmer, 
USA, CA) according to the manufacturer’s instructions. 
Briefly, PBMCs were added to the well in RPMI 1640 
medium with 10  % FCS and incubated for 18  h. Tar-
get cells were labeled with Europium-DTPA, and then 
placed in 96-well tissue culture plates then incubated with 
PBMCs at various effector-to-target (E:T) ratios. After 
incubating for 4  h at 37  °C under 5  % CO2, the release 
of Europium-DTPA was measured in a time-resolved 
fluorometer. Cytotoxicity was calculated as follows: % 
cytotoxicity =  100 ×  (experimental release −  spontane-
ous release)/(maximum release  −  spontaneous release). 
Calcein-AM(Takara Bio) was used to measure cytotoxic-
ity in cryopreserved expanded NK cells instead of Euro-
pium-DTPA, and thawed expanded NK cells was mixed 
with fluorescent-labeled target cells without pre-incuba-
tion. Finally, we calculated the values corresponding to the 
E:T ratio needed to reduce the cytotoxicity of expanded 
NK cells by 50 % of the maximum lysis value (EC50).
Clinical toxicity and efficacy assessment
Safety and toxicity were determined based on regular 
patient interviews, physical examination and laboratory 
tests. Safety was assessed and reported according to the 
National Cancer Institute Common Terminology Cri-
teria for Adverse Events (version 4.0). Objective tumor 
response was assessed by computed tomography scans 
in accordance with the Response Evaluation Criteria in 
Solid Tumor (RECIST VERSION 1.1) criteria. Disease 
assessment was performed at baseline and every 4 weeks 
after the final treatment.
Statistical analysis
The Wilcoxon signed-rank test was used to compare 
paired samples before and after NK cell therapy and 
Fig. 1 Treatment protocol. PBMCs were separated to prepare RN-T as stimulator cells. One week later, PBMCs were again separated similarly, and re-
suspended in culture medium supplemented with heat-inactivated autologous plasma, IL-2 and OK-432. RN-T cells were added to the same flask or 
culture bag on day 0 and day 7. On days 21–22, the cultured cells were harvested and administered to the patients immediately. Expanded NK cells 
were intravenously injected for 60 min on days 0, 7, 14 in a dose-escalating manner (dose 0.5 × 109, 1 × 109, 2 × 109 cells/injection, three patients/
one cohort). We investigated the dose-limiting toxicity (DLT) occurring over a 28-day period after the last administration of cultured cells. Blood 
samplings for immune monitoring were done just before the 1st and 3rd administration and 4 weeks after the 3rd administration. PBMCs peripheral 
blood mononuclear cells, RN-T cells RetroNectin®-induced T cells
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Spearman’s rank correlation tested the association 
between the two. P values of less than 0.05 were con-
sidered statistically significant. Statistical analysis 
was performed using GraphPad Prism 5 for Windows 
(GraphPad, San Diego, CA, USA).
Results
Patient characteristics
Between September 2012 and June 2013, fourteen 
patients (11 males and 3 females) were enrolled in this 
trial. Table  1 shows patient demographics and clinical 
characteristics. The median age was 65.3  years (range 
48–78). Seven (50.0  %) patients had colorectal cancer, 
four (28.6  %) had esophageal cancer, and three (21.4  %) 
had gastric cancer. Two patients in cohort 1 were 
removed from the study because the purity (no. 1, mean 
30  %) or the number (no. 2) of expanded cells did not 
meet the minimum criteria (0.35 ×  109 cells per dose). 
Two patients whose PS was 2 (no. 4 from cohort 1 and 
no. 10 from cohort 2), had disease progression during the 
NK cells preparation period and therefore received only 
two administration of NK cells.
Characteristics of expanded NK cells
PBMCs from 14 enrolled patients were cultured. The 
median of NK cell (CD3−CD56+) in lymphocytes was 
13.59 % (range 4.43–34.85). The median of total cell or 
NK cell expansion rate after 21 and 22  days of culture 
was 586-fold (range 95–1102) and 4720-fold (range 
1372–14,116), respectively (Fig.  2a). The total cell 
expansion fold did not correlate with the percentage 
of NK cells in lymphocytes (ρ = 0.24, P = 0.40), but in 
the 1st culture it significantly correlated with the cyto-
toxicity activity of PBMCs on day 0 (ρ = 0.66, P = 0.04, 
Fig. 2b). As shown in Fig. 2c, the purity of expanded NK 
(CD3−CD56+) cells markedly increased after culture, 
with the exception of one patient (Pt no. 1). The median 
purity of NK cell (CD3−CD56+) was 90.96  % (range 
65.94–99.45) in the intention-to treat (ITT) population 
and 96.14  % (range 65.94–99.45) in the per protocol 
(PP) population. As shown in Table 2 however, the per-
centage of CD3+CD56+, CD3+CD4+ and CD3+CD8+ 
cells was minimal (median 8.60, 3.50 and 0.24 %, respec-
tively). Expanded NK cells highly expressed cell surface 
markers such as NKG2D and CD16, which are consid-
ered viable and functional markers of NK cells. In the 
ITT population, the median percentage of NKG2D+ 
and CD16+ cells in NK population was 98.36 % (range 
95.20–99.59) and 61.75  % (range 20.84–73.50), respec-
tively. We also found relatively high expression lev-
els of chemokine receptors such as CXCR3, CXCR4 
and CX3CR1 on expanded NK cells (median in ITT 
population, 45.47, 37.71, and 43.74  %, respectively). 
Additional file  2: Figure  S1 shows representative flow 
Table 1 Patient characteristics
ECOG Eastern Coorperative Oncology Group, PS performance status
a Two patients were excluded from trial because the purity (no. 1) or the number (no. 2) of expanded cells didn’t exceed eligible value




Prior treatment Combined  
treatment  
(chemotherapy)
NK cell  
administration
1 1 57/M Rectal cancer Recurrent 1 Surgery, chemotherapy None Excluded from triala
2 74/F Rectal cancer Recurrent 0 Surgery, chemotherapy S-1 Excluded from triala
3 61/M Esophageal cancer Metastatic 2 Chemotherapy, radiation 
therapy
None Complete
4 62/M Gastric cancer Recurrent 2 Surgery, chemotherapy S-1 Incomplete (2 times)
5 72/M Esophageal cancer Recurrent 0 Surgery, chemotherapy None Complete
6 73/M Colon cancer Recurrent 0 Surgery, chemotherapy None Complete
7 66/M Gastric cancer Metastatic 0 Chemotherapy None Complete
2 8 62/M Esophageal cancer Recurrent 0 Surgery, chemotherapy, 
radiation therapy
None Complete
9 65/M Colon cancer Metastatic 0 Chemotherapy S-1 Complete
10 67/M Esophageal cancer Metastatic 2 Chemotherapy, radiation 
therapy
None Incomplete (2 times)
11 69/M Gastric cancer Metastatic 0 Chemotherapy None Complete
3 12 60/M Colon cancer Recurrent 0 Surgery, chemotherapy None Complete
13 78/F Rectal cancer Recurrent 0 Surgery, chemotherapy None Complete
14 48/F Rectal cancer Recurrent 0 Surgery, chemotherapy, 
radiation therapy
None Complete
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cytometry dot-plots for each population of expanded 
cells in patient no. 14.
We directly tested the cytotoxicity of each patient’s final 
product using the standard K-562 cells which is a NK-
sensitive target. Expanded cells from all patients exerted 
strong cytotoxic activity against K-562 cells (Fig.  3). At 
a 6.25:1 effector to target cell ratio, 90.29 % of the K562 
targets on average were killed by the expanded cells, and 
median EC50 value was 1.31 (range 0.39–2.61, Table 2). 
Representative data from patient no. 5, whose EC50 value 
was 0.63, appears in Additional file 3: Figure S2.
Safety assessment
The overall toxicity in the 12 ITT patients who were 
administered NK cells more than twice, is summarized 
in Table  3. No patient showed toxicity that exceeded 
grade 3. We observed one patient with grade 3 lympho-
penia (no. 3), one patient with grade 3 anorexia (no. 
10) and one patient with grade 2 pleuritis (no. 8). These 
adverse events were caused by cancer progression. Grade 
3 anorexia, fatigue, anemia, thrombocytopenia, and total 
bilirubin elevation were observed in one patient (no. 4). 
These adverse events were caused by bone marrow car-
cinomatosis and obstructive jaundice brought on by the 
progression of gastric cancer. Grade 3 neutropenia and 
anemia was observed in one patient (no. 11) adminis-
tered with S-1. These hematological toxicities were tran-
sient and were alleviated by drug withdrawal. Grade 1 
fever elevation and fatigue associated with NK cell infu-
sion was observed in one patient. The frequency and 
severity of toxicity did not increase with dose escalation 
of infused cells, and there were no severe or unexpected 
toxicity related to the NK cell infusion. Thus, the maxi-
mum tolerated dose was not reached.
Clinical efficacy
The evaluation of clinical outcome is shown in Table  4. 
No patient showed tumor shrinkage during the observa-
tion period up to 4  weeks after their last treatment. Of 
the 12 ITT patients, 5 (41.7 %) presented stable disease 
Fig. 2 Expansion and NK purity dynamics of PBMCs obtained from 14 patients. a Fold expansion of total cell and NK cell population (CD3−CD56+ 
cell) during the culture period. Dots represent mean values of each patient in triplicate cultures. Horizontal bars indicate median values. b Relation 
of NK cell expansion fold and cytotoxic activity of PBMCs. Expansion fold of NK cells in the first culture significantly correlated with cytotoxic activity 
of PBMCs at baseline (ρ = 0.661, p = 0.044). PBMCs peripheral blood mononuclear cells. c The purity of NK cell population (CD3−CD56+ cell) at 
baseline and 21 or 22 days after the initiation of the culture
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(SD) and 7 (58.3  %) presented progressive disease (PD). 
Of the 10 PP patients, 5 (50 %) presented SD and 5 (50 %) 
presented PD. Thus, in the PP analysis, the response 
rate and the disease control rate (DCR, complete 
response + partial response +  SD) in this study were 0 
and 50.0 %, respectively.
Fig. 3 Cytotoxic activity of expanded NK cells against K-562 cells. 4 h cytotoxicity from 14 patients against K-562 target cells. Mean cell death in 
each patient at the indicated E:T ratios in triplicate cultures
Table 3 Maximum toxicity per patient
Toxicity Cohort 1 (n = 5) Cohort 2 (n = 4) Cohort 3 (n = 3) All cohort 
(n = 12)
Grade Grade Grade Grade
1–2 3 1–2 3 1–2 3 1–2 3
Hematological
 Neutropenia 0 0 1 0 0 1 1 1
 Lymphopenia 3 1 3 0 0 0 6 1
 Anemia 3 1 3 1 2 0 8 2
 Thrombocytopenia 2 1 1 0 0 0 3 1
 Elevated AST 2 0 1 0 0 0 3 0
 Elevated ALT 0 0 1 0 0 0 1 0
 Elevated total billirubin 0 1 2 0 1 0 3 1
Non-hematological
 Fatigue 2 0 3 0 3 0 8 0
 Fever 1 0 0 0 0 0 1 0
 Anorexia 0 1 0 1 0 0 0 2
 Nausea 0 0 0 0 2 0 2 0
 Diarrhea 0 0 2 0 0 0 2 0
 Constipation 1 0 2 0 0 0 3 0
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Immunological monitoring
Immunological monitoring was performed for per proto-
col evaluable patients using their PBMCs before and after 
the NK cells infusion. As indicated in Fig. 4a and Addi-
tional file 4: Table S2, the average NK cell population in 
peripheral blood lymphocytes (PBLs) slightly increased 
until day 42 after NK cell infusion. Evaluated by cohort, 
the population of NK cells in cohort 2 and 3 increased 
after the infusion of NK cells, whereas there was a grad-
ual decrease in cohort 1 (Fig.  4b). Next, we tested the 
cytotoxicity of PBMCs against K-562 targets and found 
that cytotoxicity increased in 80  % of patients after NK 
cell infusion (Additional file 5: Table S3). On day 14, aver-
age PBMC cytotoxic increased more than twice the day 0 
baseline value; while it gradually decreased, it remained 
higher than day 0 until day 42 (Fig.  5a). This change in 
Table 4 Tumor response
ITT intention -to-treat, PP per protocol, CR complete response, PR Partial response, SD stable disease, PD progressive disease, 95 %CI 95 % confidence interval
No. of patients Response Response rate (%)  
(95 % CI)
Disease control rate (%) 
(95 % CI)
CR PR SD PD
ITT population n = 12 0 0 5 7 0 (0) 41.7 (15.17–72.33)
PP population n = 10 0 0 5 5 0 (0) 50.0 (18.71–81.29)
Fig. 4 Longitudinal plots of NK cell population in PBLs plotted according to their deviation from the baseline. Mean levels in all patients (a) and 
levels in each cohort (b) are shown. PBLs peripheral blood lymphocytes
Fig. 5 Longitudinal plots of cytotoxic activity of PBMCs against K-562 cells plotted according to the deviation from the baseline. Mean levels in 
all patients at indicated E:T ratios (a blue 20:1, red 40:1) and levels for the tumor responses at 40:1 E/T ratio (b) are shown. PBMCs peripheral blood 
mononuclear cells, SD stable disease, PD progressive disease
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PBMC cytotoxic activity was similar across all cohorts 
and seemed to be independent of the number of cells that 
were infused. However, PBMC cytotoxic activity differed 
according to objective tumor response, and the average 
in patients with SD increased more than three times on 
day 14 and was much higher than in patients with PD 
(Fig.  5b). Cytokine serum levels did not change signifi-
cantly after NK cell infusion (Table 5).
Discussion
In this phase I clinical trial consisting of advanced diges-
tive cancer patients, we explored the safety and feasibil-
ity of adoptive transfer of NK cells elicited by a novel 
expansion method using RN-T cells. We generated pure 
(median 90.96 %) NK cells on a large scale without prior 
purification. These cells expressed activating markers 
such as NKG2D and CD16 implicated in cytotoxicity 
and ADCC activity and exerted strong cytotoxic activ-
ity against K-562 cells in  vitro. Not only did our pro-
posed method produce fully functional NK cells in large 
numbers, the process was safe, well tolerated and highly 
reproducible.
NK cells occur in low numbers in PBMCs and obtaining 
the number necessary for adoptive transfer of NK cells 
is technically challenging. Unlike T cells, which read-
ily respond to a variety of stimuli, it is generally difficult 
to expand NK cells from a small amount of blood from 
patients with advanced cancer who in general tend to 
have impaired immune function. There are few previous 
reports in which a NK cell expansion method produced 
pure cells in sufficient quantities from a small amount 
of blood without prior purification of the NK cells [26]. 
IL-2 can induce proliferative responses in human NK 
cells, but as suggested by existing reports, it can induce 
up to a 50-fold expansion after being cultured for 2 weeks 
[27–29]. Recently, Alici et al. reported that anti-CD3 and 
IL-2 induced 1600-fold NK expansions after 20 days from 
the blood of patients with myeloma [30]. However, the 
cytotoxicity of these cells against K562 cells was <10 % at 
1:1 E/T ratio [30], which is much lower than the results 
achieved in this present in vitro study (average cytotoxic-
ity 57.54 or 38.77 % at 1.56:1 or 0.75:1 E/T ratio).
We observed that chemokine receptors CXCR3, 
CXCR4 and CX3CR1 were relatively highly expressed in 
expanded NK cells, with a median in the ITT population, 
of 45.47, 37.71, 43.74 % respectively. These molecules are 
considered to be involved in the accumulation of intra-
tumoral NK cells [31–34]. Thus, the NK cells elicited by 
our system are believed to have excellent properties as 
adoptive transferred cell in cancer immunotherapy. The 
percentage of CD16+ NK cells in the final product was 
relatively low compared to that observed in our previous 
study (average 55.4 vs 96.8 %) [25]. We observed by flow 
cytometer that CD16 expression on NK cells decreased 
approximately 30 % after being thawed and this may be 
attributed to us using thawed samples in the present 
study, whereas fresh samples were analyzed in our previ-
ous study.
Although no clinical responses were observed in 10 
PP patients, the in  vitro cytotoxicity of PBMCs against 
K-562 targets increased in 80 % of patients post adoptive 
NK cell transfer. The average cytotoxic activity on day 14 
increased more than two times after NK cells infusion, 
and the increase continued until day 42 post-transfer. In 
their clinical trial for patients with metastatic melanoma 
or renal cell carcinoma, Parkhurst et  al. documented 
the persistence, function and phenotype of autologous 
NK cells after adoptive transfer [35]. In their study, the 
peripheral blood lymphocyte 1  week post treatment 
Table 5 Serum cytokines concentration before  and 
after NK cell therapy
Values are expressed as the mean ± SD. The paired t test was used to determine 
statistical differences
NS not significant
Baseline (day 0)  
(pg/ml)
Post administration  
(day 42) (pg/ml)
p value
IL-1β 4.007 ± 7.155 6.438 ± 13.22 0.25
IL-1RA 893.3 ± 2154 983.0 ± 2550 1
IL-2 37.16 ± 22.54 37.45 ± 29.48 0.8203
IL-4 2.456 ± 0.6683 2.600 ± 0.7691 0.4961
IL-5 4.029 ± 2.191 4.171 ± 3.156 1
IL-6 38.62 ± 47.26 45.43 ± 58.69 0.3594
IL-7 3.827 ± 3.984 4.724 ± 6.224 0.8203
IL-8 26.94 ± 9.571 30.73 ± 16.71 0.4258
IL-9 31.33 ± 28.77 32.87 ± 37.69 0.4258
IL-10 26.28 ± 30.72 27.71 ± 39.37 0.3008
IL-12p70 37.28 ± 50.31 47.22 ± 83.46 0.9102
IL-13 14.87 ± 21.99 19.05 ± 36.70 0.8203
IL-15 44.33 ± 20.73 43.67 ± 28.17 0.8203
IL-17 199.2 ± 89.43 185.1 ± 109.2 0.4961
IFN-γ 92.13 ± 119.4 105.4 ± 141.8 0.3594
TNF-α 32.04 ± 45.28 38.69 ± 59.64 0.0977
bFGF 51.92 ± 31.51 53.38 ± 45.84 0.7344
PDGF-BB 172.2 ± 108.3 191.0 ± 219.0 0.9102
G-CSF 55.23 ± 26.89 58.08 ± 40.79 0.9102
GM-CSF 90.58 ± 75.85 94.29 ± 97.23 0.7344
IP-10 287.1 ± 40.88 389.2 ± 204.4 0.3008
MCP-1 133.6 ± 33.18 122.1 ± 52.29 0.2031
MIP-1α 4.972 ± 3.239 4.214 ± 2.073 0.1641
MIP-1β 275.0 ± 86.68 300.6 ± 154.0 1
Eotaxin 116.4 ± 193.8 123.2 ± 233.4 0.7344
RANTES 2157 ± 396.8 2445 ± 580.7 0.2031
VEGF 92.02 ± 30.85 113.2 ± 79.16 0.9102
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consisted of an average of 83 % NK cells, which was much 
higher than in our clinical study (21 % at 2 weeks post-
transfer). This difference in results probably stems from 
the higher number of transferred cells used in their clini-
cal trial (47 × 109 per dose) versus the current trial (0.5 
or 1.0 or 2.0  ×  109 per dose). Additionally, their study 
involved lymph depleting chemotherapy and systemic 
IL-2 administration combined with NK cell transfer; 
these procedures were not done in our trial.
As previously mentioned, the focus of this clinical trial 
was to assess the safety of the NK cells produced with 
our expansion method. These cells had a relatively high 
level of functionality which made them promising how-
ever, we felt it was also important to know their level of 
toxicity before focusing on their efficacy. For this reason, 
although studies like those presented above have received 
better efficacy with combined treatment such as lymph 
depletion and any cytokine support, we chose a mono-
therapy where a relatively small number of NK cells were 
administered as the best option to assess the safety of the 
expanded cells.
To overcome the limited clinical efficacy of NK cell-
based monotherapy, several strategies have been sug-
gested including the combination of various monoclonal 
antibodies [26]. Within the setting of NK cell-based 
therapy, much attention has been given to the KIR-ligand 
mismatch phenomenon. Lack of KIR-HLA class I inter-
actions has been associated with potent NK-mediated 
antitumor efficacy in acute myeloid leukemia patients 
upon haplo-identical stem cell transplantation [36] or 
NK cells infusion [6, 37] from KIR mismatched donors. 
Thus, a KIR ligand-mismatched donor is likely to provide 
the best chance for clinical response. Adoptive transfer 
of allogeneic NK cells from a KIR ligand-mismatched 
donor elicited by our novel method is expected to offer 
advantages over autologous NK cells. Since our method 
does not stimulate T cell proliferation, this could be 
an important clinical advantage because it avoids the 
risk of graft-versus-host disease in allogeneic NK cell 
therapy. Immune checkpoint blockade with antibod-
ies to CTLA-4 and PD-1 represents a promising can-
cer therapy that aims to restore an efficient antitumoral 
response mediated by T cell [38]. As a corollary to tar-
geting negative regulators of T cells, blocking inhibitory 
signals of NK cells with anti-KIR [39] or anti-Tim-3 [40] 
antibodies is also an attractive therapy to combine with 
NK cell therapy. CD16 expression of expanded NK cells 
produced in our study is relatively high. Therefore, adop-
tive transfer of these NK cells combined with tumor-spe-
cific monoclonal antibodies has the potential to trigger 
strong ADCC responses. This type of combined therapy 
with IgG1 monoclonal antibodies is likely to be promis-
ing. Having confirmed that our expanded cells are safe 
to administer, we are currently conducting clinical trials 
combining them with cetuximab for colorectal cancer 
and trastuzumab for gastric cancer patients in order to 
assess their efficacy. (The UMIN Clinical Trials Registry 
ID: UMIN000013378).
Conclusion
We have shown that our novel NK expansion system using 
RN-T cells is effective at producing large numbers of fully 
functional NK cells that are pure. The data here also dem-
onstrates that adoptive transfer of these NK cells is safe 
and very well tolerated by patients who had failed stand-
ard cancer therapy. NK cell transfer as a monotherapy is 
generally unsatisfactory and although no clinical responses 
were observed in patients, knowing that these cells can 
be safely administered will allow us to make an attempt 
at improving their efficacy by combining them with other 
reagents. We believe that these expanded cells have the 
potential to be efficacious in a combination treatment, 
since we observed that transferred NK cells persisted in 
the peripheral circulation of patients and exerted cyto-
toxicity in vitro. The NK cell expansion method suggested 
here could be applied to various NK cell-based therapies 
and can be combined with a range of treatment modalities. 
The advantage of our novel NK cell generation method can 
be summarized as follows: (1) large number of highly pure 
and functional cells (2) no need for purification including 
the use of a magnetic beads sorting system (3) improved 
safety through the use of autologous RN-T cells rather 
than transgenic or cancer cells as a stimulator (4) requires 
only a small amount of blood (5) requires low-serum cul-
ture conditions (0.5–1.0  %) and (6) high reproducibility. 
We believe that this expansion method is an innovative 
tool for NK cell-based cancer immunotherapy.
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